Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

BPH

Signal of GV1001 efficacy

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

Original article

  1. Moon, K. T. et al. A randomised, placebo-controlled, multicentre, phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia. BJU Int. https://doi.org/10.1111/bju.14233 (2018)

    Article  Google Scholar 

Further reading

  1. Graham, M. K. et al. Telomeres and telomerase in prostate cancer development and therapy. Nat. Rev. Urol. 14, 607–619 (2017)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Clemens Thoma.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Thoma, C. Signal of GV1001 efficacy. Nat Rev Urol 15, 466–467 (2018). https://doi.org/10.1038/s41585-018-0030-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-018-0030-0

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing